Philip H. Coelho net worth and biography

Philip Coelho Biography and Net Worth

Philip H. Coelho, Founder and Chief Technology Officer (CTO)of Thermogenesis Corp., is an engineer and inventor, educated at the University of California, Davis, where he specialized in thermodynamics and machine design. He holds more than 40 U.S. patents related to cell selection, cell cryopreservation, cell washing, automated cryogenic freezing and storage of cells and harvesting clotting proteins from blood. As Founder, Chairman and CEO of Thermogenesis Corp., Mr. Coelho developed the Thermoline ultra rapid blood plasma freezer and thawer; the CryoSeal automated system for preparing fibrin sealant from a surgical patient’s blood; the BioArchive robotic system for controlled-rate freezing and cryogenically archiving units of hematopoietic stem and progenitor cells (HSPCs) derived from placental/cord blood; and the AutoXpress System, which automates harvesting of HSPCs from cord blood into a 25 ml dual-compartment freezing bag. The BioArchive and AutoXpress Systems have established the highest quality GMP standards in cord blood processing and banking worldwide. Mr. Coelho retired from Thermogenesis Corp in August 2007. In 2009, Mr. Coelho co-founded SynGen Inc., and began the development of programmable systems that improve the speed and efficiency of the isolation and capture of purified stem, progenitor and immune cells residing within peripheral or placental/cord blood, bone marrow aspirate and leukapheresis. In July 2017, SynGen merged with Thermogenesis Corp, now a subsidiary of Cesca Therapeutics, and Mr. Coelho accepted the position of CTO in the combined company. He is now leading the development of CAR-TXpress, an automated method of manufacturing therapeutic doses of CAR T-cells in a functionally closed cell processing system. Mr. Coelho has been a member of the Catalyst Board of Directors since October 2002.

What is Philip H. Coelho's net worth?

The estimated net worth of Philip H. Coelho is at least $3.10 million as of November 21st, 2022. Mr. Coelho owns 179,553 shares of Catalyst Pharmaceuticals stock worth more than $3,100,880 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Coelho may own. Learn More about Philip H. Coelho's net worth.

How do I contact Philip H. Coelho?

The corporate mailing address for Mr. Coelho and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected] Learn More on Philip H. Coelho's contact information.

Has Philip H. Coelho been buying or selling shares of Catalyst Pharmaceuticals?

Within the last three months, Philip H. Coelho has sold $1,240,582.55 in Catalyst Pharmaceuticals stock. Most recently, Philip H. Coelho sold 9,999 shares of the business's stock in a transaction on Wednesday, November 23rd. The shares were sold at an average price of $17.45, for a transaction totalling $174,482.55. Following the completion of the sale, the director now directly owns 149,553 shares of the company's stock, valued at $2,609,699.85. Learn More on Philip H. Coelho's trading history.

Who are Catalyst Pharmaceuticals' active insiders?

Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Alicia Grande (CFO), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), and Steven Miller (COO & Chief Scientific Officer ). Learn More on Catalyst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Catalyst Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 24 times. They sold a total of 1,742,297 shares worth more than $26,268,304.10. The most recent insider tranaction occured on November, 23rd when COO Steve Miller sold 20,000 shares worth more than $346,800.00. Insiders at Catalyst Pharmaceuticals own 14.1 % of the company. Learn More about insider trades at Catalyst Pharmaceuticals.

Information on this page was last updated on 11/23/2022.

Philip H. Coelho Insider Trading History at Catalyst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2022Sell9,999$17.45$174,482.55149,553View SEC Filing Icon  
11/21/2022Sell70,000$15.23$1,066,100.00179,553View SEC Filing Icon  
8/25/2021Sell9,498$5.56$52,808.88233,427View SEC Filing Icon  
6/17/2016Buy15,000$0.76$11,400.00159,987View SEC Filing Icon  
3/17/2016Buy10,000$1.06$10,600.00158,287View SEC Filing Icon  
11/15/2012Buy24,000$0.41$9,840.00View SEC Filing Icon  
See Full Table

Philip H. Coelho Buying and Selling Activity at Catalyst Pharmaceuticals

This chart shows Philip H Coelho's buying and selling at Catalyst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Read More

Today's Range

Now: $17.27
Low: $16.51
High: $17.55

50 Day Range

MA: $14.28
Low: $12.09
High: $17.51

2 Week Range

Now: $17.27
Low: $5.24
High: $18.39

Volume

3,382,300 shs

Average Volume

1,969,081 shs

Market Capitalization

$1.80 billion

P/E Ratio

28.31

Dividend Yield

N/A

Beta

1.25